DNTH Dianthus Therapeutics, Inc.

NASDAQ
$106.20

Dianthus Therapeutics, Inc. (DNTH) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

30D 90D 6M 1Y
Insider signal In line Selling ran in line with DNTH's own trailing one-year pace, with 80% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 5 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
8
58 transactions
Purchases
$0
0 shares
Sales
$66.7M
855,435 shares
Net activity
-$66.7M
purchases less sales

How much of that selling was preplanned? 80% planned / 20% discretionary

10b5-1 plan sales $53.1M 56 transactions · 729,435 shares
Discretionary sales $13.6M 2 transactions · 126,000 shares

Largest single sale: $11.2M.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Read Simon Director Sell 10b5-1 2,778 $117.55 $326.6K None left
Veness Adam M SVP, General Counsel and Sec. Sell 10b5-1 16,167 $110.38 $1.8M None left
McGeorge Anne 5 fills Director Sell 10b5-1 7,750 $109.01 $844.8K 6,300 −55.2% of holding
Read Simon 6 fills Director Sell 10b5-1 2,777 $109.55 $304.2K 2,707 −50.6% of holding
Garcia Marino 2 fills CEO AND PRESIDENT Sell 126,000 $108.09 $13.6M 87,102 −59.1% of holding
Garcia Marino 5 fills CEO AND PRESIDENT Sell 10b5-1 40,000 $108.15 $4.3M 220,908 −15.3% of holding
Veness Adam M 2 fills SVP, General Counsel and Sec. Sell 10b5-1 3,833 $110.70 $424.3K 616 −86.2% of holding
Savitz Ryan 3 fills EVP, CFO & CBO Sell 10b5-1 31,249 $101.03 $3.2M 20,895 −59.9% of holding
Veness Adam M 2 fills SVP, General Counsel and Sec. Sell 10b5-1 30,000 $80.80 $2.4M 13,229 −69.4% of holding
Randhawa Simrat 3 fills EVP, Head of R&D Sell 10b5-1 26,530 $90.62 $2.4M 25,102 −51.4% of holding
Soteropoulos Paula Director Sell 10b5-1 599 $85.47 $51.2K None left
Savitz Ryan EVP, CFO & CBO Sell 10b5-1 8,224 $89.84 $738.8K None left
Savitz Ryan 8 fills EVP, CFO & CBO Sell 10b5-1 114,367 $83.00 $9.5M 112,977 −50.3% of holding
Soteropoulos Paula Director Sell 10b5-1 599 $80.11 $48.0K None left
Soteropoulos Paula Director Sell 10b5-1 27,594 $78.05 $2.2M None left
Garcia Marino 5 fills CEO AND PRESIDENT Sell 10b5-1 122,918 $81.49 $10.0M 79,413 −60.8% of holding
CARR EDWARD 5 fills CHIEF ACCOUNTING OFFICER Sell 10b5-1 43,682 $81.49 $3.6M 27,830 −61.1% of holding
Randhawa Simrat EVP, Head of R&D Sell 10b5-1 33,830 $81.48 $2.8M None left
Savitz Ryan CFO & CBO Sell 10b5-1 20,000 $45.18 $903.6K None left
Randhawa Simrat EVP, Head of R&D Sell 10b5-1 109,031 $38.14 $4.2M 4,000 −96.5% of holding
Randhawa Simrat 3 fills EVP, Head of R&D Sell 10b5-1 87,507 $36.81 $3.2M 65,341 −57.3% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.